Back to Search
Start Over
[The effect of immunotherapy with thymopentin on the parameters of cellular immunity and the clinical course of gynecologic tumor patients].
- Source :
-
Onkologie [Onkologie] 1989 Jun; Vol. 12 Suppl 3, pp. 15-21. - Publication Year :
- 1989
-
Abstract
- In 25 patients with cervical, uterine and ovarian cancer with a depletion of T-helper cells and a lack of reactivity in the LMI-Test a course of immunotherapy with thymopentin (Timunox, Cilag Biotech) at a dosage of 100 mg/die for 2 weeks and subsequently 100 mg 3 x/week for 4 weeks was performed and a comparison was made with a control group of 59 patients receiving no immunotherapy. The following parameters of cell-mediated immunity were determined: (1) leucocyte-migration-inhibition-test (LMI-test) against the tumor and varidase, and (2) number of T-helper/inducer-, T-suppressor/cytotoxic-, total T-, and natural killer cells in the peripheral blood. After a course of immunotherapy no changes in the mean value of the percentage of the cell-subpopulations could be observed, but in a quarter of all patients a reaction in the LMI-test could be shown. In the control group, under chemotherapy, the percentage of T-helper-, T-suppressor- and total T-cells decreased strongly, whereas in the immunotherapy group the percentage of these populations remained unchanged. Under the restriction of a mean observation time of only 18 (5-32) months no differences concerning the survival time between both groups could be observed; only in advanced ovarian cancer patients could a slight positive effect of immunotherapy be shown. These results support the indication of a course of immunotherapy with thymopentin in combination with chemotherapy, especially in advanced cancer patients.
- Subjects :
- Antineoplastic Combined Chemotherapy Protocols therapeutic use
Cell Migration Inhibition
Combined Modality Therapy
Female
Genital Neoplasms, Female immunology
Genital Neoplasms, Female pathology
Humans
Leukocyte Count drug effects
Neoplasm Staging
Ovarian Neoplasms therapy
T-Lymphocytes, Helper-Inducer immunology
T-Lymphocytes, Regulatory immunology
Thymopentin
Uterine Cervical Neoplasms therapy
Uterine Neoplasms therapy
Adjuvants, Immunologic administration & dosage
Genital Neoplasms, Female therapy
Immunity, Cellular drug effects
Immunotherapy methods
Peptide Fragments administration & dosage
Thymopoietins administration & dosage
Thymus Hormones administration & dosage
Subjects
Details
- Language :
- German
- ISSN :
- 0378-584X
- Volume :
- 12 Suppl 3
- Database :
- MEDLINE
- Journal :
- Onkologie
- Publication Type :
- Academic Journal
- Accession number :
- 2532730
- Full Text :
- https://doi.org/10.1159/000216698